daratumumab,lenalidomide,dexamethasone,carfilzomib
janssen
['master trial', 'mmsm']
#eha2023 | luciano costa shares a final analysis of the master trial on quadruplet dara-krd, asct and mrd-modulated consolidation in ndmm. mrd neg 81%. pfs 88%, 79%, 50% in 0, 1 and 2+ hrca, os 94%, 92% and 75%. #mmsm #myeloma 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma